Whitehawk Therapeutics Inc
WHWK · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.03 | 0.07 |
| FCF Yield | -40.99% | -25.75% | -17.80% | -28.50% |
| EV / EBITDA | 0.30 | 11.82 | -3.17 | -2.43 |
| Quality | ||||
| ROIC | -31.82% | -6.86% | -35.41% | -19.10% |
| Gross Margin | 0.00% | 89.36% | -109.10% | -49.76% |
| Cash Conversion Ratio | 1.01 | -0.16 | 0.82 | 1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.80% | 0.09% | 13.94% | 19.53% |
| Free Cash Flow Growth | -326.56% | 18.53% | 4.01% | -63.69% |
| Safety | ||||
| Net Debt / EBITDA | 2.76 | 15.00 | 1.53 | 2.76 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -352.97 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.85 | 1.98 |
| Cash Conversion Cycle | -18,781.88 | -433.07 | 92.13 | 115.73 |